• 12-month exclusive agreement with global animal reproduction leader IMV Technologies
• IMV is a global market leader with over 500 million animal inseminations annually
• Partnership to integrate Vitrafy's cryopreservation technology with IMV's offerings

Vitrafy Life Sciences Limited (ASX: VFY) has entered into a Collaboration and Development Agreement with IMV Technologies, SA ('IMV'), a global leader in animal reproductive technologies. The 12-month strategic collaboration aims to co-develop a market-ready solution that combines the strengths of both organizations, including expertise, product portfolios, and scientific innovation, to establish a new benchmark in reproductive cryopreservation across farm animals and aquaculture. Upon successful completion of the program, it is anticipated that a long-term commercial agreement between Vitrafy and IMV will be executed, enabling IMV to deliver Vitrafy's cryopreservation service offering to the global animal market and accelerate adoption. By partnering with the global leader for animal reproduction, Vitrafy is executing on its strategy of accelerating commercial scale in the unregulated animal reproduction market, while continuing to focus resources on the expansion efforts for the human health market in North America. Under the agreement, Vitrafy will be paid a monthly fee of up to A$480,000 for the 12-month term, plus the ability to secure milestone payments of A$450,000 for the successful achievement of pre-determined milestones. Both parties have the ability to extend the agreement for a further 6 months, which will correspond to an extension and increase of the monthly fee.

The partnership aims to jointly commercialize a global cryopreservation offering for farm animals and aquaculture, leveraging Vitrafy's unique nitrogen-free cryopreservation technology and IMV's global leadership in animal reproduction.